Syndax Pharmaceuticals vs Zai Lab
SNDX and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SNDX and ZLAB compare
Zai Lab is the larger company, worth 45 times as much as Syndax Pharmaceuticals ($38.2B against $844M).
Syndax Pharmaceuticals grew revenue faster over the last twelve months (160% versus 0.02% for Zai Lab).
Zai Lab keeps more of each dollar of sales as profit, with a net margin of −44.9% compared with −72.3% at Syndax Pharmaceuticals.
Zai Lab scores higher on the StockData Score (6 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SNDX | ZLAB |
|---|---|---|
| Size and price | ||
| Market cap | $844M | $38.2B |
| Share price | $9.45 | $24.60 |
| Change, 1 year | −43.7% | 12.4% |
| Change, 5 years | −46.8% | −70.8% |
| Beta (5Y) | 1.07 | 1.10 |
| Employees | 298 | 1,784 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.9× (better) | 86.5× |
| P/B | – | 67.8× |
| FCF yield | – | −0.43% |
| Fair value | – | $4.31 |
| Margin of safety | – | −471% |
| Growth | ||
| Revenue growth (TTM) | 160% (better) | 0.02% |
| Revenue growth, 5Y average | 158% (better) | 56.5% |
| Profitability | ||
| Gross margin | – | 54.7% |
| Operating margin | −61.7% (better) | −63.0% |
| Net margin | −72.3% | −44.9% (better) |
| FCF margin | – | −37.0% |
| Return on equity | −426% | −30.0% (better) |
| Return on invested capital | – | −87.6% |
| Financial health | ||
| Debt / equity | – | 0.45 |
| Interest coverage | −44660.0× | −45.2× (better) |
| Current ratio | 4.69 (better) | 2.04 |
| Altman Z-score | −2.28 | 46.02 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 121% | 2.8% |
| Held by insiders | 1.8% | 0.67% |
| Insider net buying, 12 months | −$2.9M (better) | −$10.8M |
| Short interest, % of float | 21.6% | – |
Go deeper
- SNDX stock overview
- SNDX income statement
- SNDX valuation and score
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.